A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein

Abstract Background Fibroblast activation protein (FAP) targeting radiotracers have emerged as promising agents for cancer imaging and therapy. Recent advancements have focused on optimizing these agents for better tumor targeting and enhanced theranostic efficacy. In this study, we introduced a nov...

Full description

Saved in:
Bibliographic Details
Main Authors: Chengde Xie, Lei Peng, Hui Nie, Tianhong Yang, Renbo Wu, Dake Zhang, Fuhua Wen, Junyu Chen, Lingyu Xue, Xiangsong Zhang, Zhihao Zha, Jianjun Wang
Format: Article
Language:English
Published: SpringerOpen 2025-05-01
Series:EJNMMI Research
Subjects:
Online Access:https://doi.org/10.1186/s13550-025-01230-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850284591846260736
author Chengde Xie
Lei Peng
Hui Nie
Tianhong Yang
Renbo Wu
Dake Zhang
Fuhua Wen
Junyu Chen
Lingyu Xue
Xiangsong Zhang
Zhihao Zha
Jianjun Wang
author_facet Chengde Xie
Lei Peng
Hui Nie
Tianhong Yang
Renbo Wu
Dake Zhang
Fuhua Wen
Junyu Chen
Lingyu Xue
Xiangsong Zhang
Zhihao Zha
Jianjun Wang
author_sort Chengde Xie
collection DOAJ
description Abstract Background Fibroblast activation protein (FAP) targeting radiotracers have emerged as promising agents for cancer imaging and therapy. Recent advancements have focused on optimizing these agents for better tumor targeting and enhanced theranostic efficacy. In this study, we introduced a novel heterodimeric radioligand labeled with gallium-68, which targets FAP. We aimed to evaluate its in vitro and in vivo performance, comparing its efficacy with monomeric FAPI derivatives. Results The heterodimeric ligand BiFAPI was synthesized by conjugating a cyclic peptide with a quinoline-based motif via a DOTA chelator. [68 Ga]Ga-BiFAPI demonstrated high radiochemical purity (> 95%) and exceptional stability in physiological conditions, as well as in both PBS and serum. In vitro studies revealed that the binding affinity of BiFAPI was comparable to that of FAP2286 and FAPI-04. Notably, [68 Ga]Ga-BiFAPI exhibited superior cellular uptake, with rapid internalization and slower efflux rates. Micro-PET/CT imaging in tumor-bearing mice demonstrated significantly higher tumor uptake than [68 Ga]Ga-FAP2286 and [68 Ga]Ga-FAPI-04. Co-injection with a FAP inhibitor reduced tumor uptake, confirming the tracer’s FAP specificity. In vitro autoradiography, immunohistochemistry, and Western blotting confirmed the correlation between radioactive tracer accumulation and FAP-positive regions. Biodistribution studies revealed high tumor-to-blood ratios and rapid clearance from non-target tissues, further supporting the tracer’s favorable pharmacokinetics. Conclusion [68 Ga]Ga-BiFAPI demonstrated superior tumor-targeting properties, higher tumor uptake, and favorable pharmacokinetics compared to [68 Ga]Ga-FAP2286 and [68 Ga]Ga-FAPI-04. Its promising performance in preclinical models positioned it as a potentially valuable agent for FAP-targeted PET imaging and cancer theranostics.
format Article
id doaj-art-d95d8b5c69234ca481b8559ee229c29f
institution OA Journals
issn 2191-219X
language English
publishDate 2025-05-01
publisher SpringerOpen
record_format Article
series EJNMMI Research
spelling doaj-art-d95d8b5c69234ca481b8559ee229c29f2025-08-20T01:47:32ZengSpringerOpenEJNMMI Research2191-219X2025-05-0115111010.1186/s13550-025-01230-wA heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation proteinChengde Xie0Lei Peng1Hui Nie2Tianhong Yang3Renbo Wu4Dake Zhang5Fuhua Wen6Junyu Chen7Lingyu Xue8Xiangsong Zhang9Zhihao Zha10Jianjun Wang11MOE Key Laboratory of Resources and EnvironmentalSystems Optimization, College of Environmental Scienceand Engineering, North China Electric Power UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityMOE Key Laboratory of Resources and EnvironmentalSystems Optimization, College of Environmental Scienceand Engineering, North China Electric Power UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityDepartment of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen UniversityMOE Key Laboratory of Resources and EnvironmentalSystems Optimization, College of Environmental Scienceand Engineering, North China Electric Power UniversityAbstract Background Fibroblast activation protein (FAP) targeting radiotracers have emerged as promising agents for cancer imaging and therapy. Recent advancements have focused on optimizing these agents for better tumor targeting and enhanced theranostic efficacy. In this study, we introduced a novel heterodimeric radioligand labeled with gallium-68, which targets FAP. We aimed to evaluate its in vitro and in vivo performance, comparing its efficacy with monomeric FAPI derivatives. Results The heterodimeric ligand BiFAPI was synthesized by conjugating a cyclic peptide with a quinoline-based motif via a DOTA chelator. [68 Ga]Ga-BiFAPI demonstrated high radiochemical purity (> 95%) and exceptional stability in physiological conditions, as well as in both PBS and serum. In vitro studies revealed that the binding affinity of BiFAPI was comparable to that of FAP2286 and FAPI-04. Notably, [68 Ga]Ga-BiFAPI exhibited superior cellular uptake, with rapid internalization and slower efflux rates. Micro-PET/CT imaging in tumor-bearing mice demonstrated significantly higher tumor uptake than [68 Ga]Ga-FAP2286 and [68 Ga]Ga-FAPI-04. Co-injection with a FAP inhibitor reduced tumor uptake, confirming the tracer’s FAP specificity. In vitro autoradiography, immunohistochemistry, and Western blotting confirmed the correlation between radioactive tracer accumulation and FAP-positive regions. Biodistribution studies revealed high tumor-to-blood ratios and rapid clearance from non-target tissues, further supporting the tracer’s favorable pharmacokinetics. Conclusion [68 Ga]Ga-BiFAPI demonstrated superior tumor-targeting properties, higher tumor uptake, and favorable pharmacokinetics compared to [68 Ga]Ga-FAP2286 and [68 Ga]Ga-FAPI-04. Its promising performance in preclinical models positioned it as a potentially valuable agent for FAP-targeted PET imaging and cancer theranostics.https://doi.org/10.1186/s13550-025-01230-wFAPPET imagingHeterodimericTheranostics
spellingShingle Chengde Xie
Lei Peng
Hui Nie
Tianhong Yang
Renbo Wu
Dake Zhang
Fuhua Wen
Junyu Chen
Lingyu Xue
Xiangsong Zhang
Zhihao Zha
Jianjun Wang
A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein
EJNMMI Research
FAP
PET imaging
Heterodimeric
Theranostics
title A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein
title_full A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein
title_fullStr A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein
title_full_unstemmed A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein
title_short A heterodimeric radioligand labeled with gallium-68 targeting fibroblast activation protein
title_sort heterodimeric radioligand labeled with gallium 68 targeting fibroblast activation protein
topic FAP
PET imaging
Heterodimeric
Theranostics
url https://doi.org/10.1186/s13550-025-01230-w
work_keys_str_mv AT chengdexie aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT leipeng aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT huinie aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT tianhongyang aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT renbowu aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT dakezhang aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT fuhuawen aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT junyuchen aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT lingyuxue aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT xiangsongzhang aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT zhihaozha aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT jianjunwang aheterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT chengdexie heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT leipeng heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT huinie heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT tianhongyang heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT renbowu heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT dakezhang heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT fuhuawen heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT junyuchen heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT lingyuxue heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT xiangsongzhang heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT zhihaozha heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein
AT jianjunwang heterodimericradioligandlabeledwithgallium68targetingfibroblastactivationprotein